CR8935A - Inhibidores de la arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones - Google Patents

Inhibidores de la arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones

Info

Publication number
CR8935A
CR8935A CR8935A CR8935A CR8935A CR 8935 A CR8935 A CR 8935A CR 8935 A CR8935 A CR 8935A CR 8935 A CR8935 A CR 8935A CR 8935 A CR8935 A CR 8935A
Authority
CR
Costa Rica
Prior art keywords
rna
hepatitis
virus
inhibitors
compositions
Prior art date
Application number
CR8935A
Other languages
English (en)
Inventor
Gonzalez Javier
Michelle Jewell Tanya
Li Hui
Linton Angelica
Howard Tatlock John
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CR8935A publication Critical patent/CR8935A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion proporciona compuestos de formula (4) y sus sales farmaceuticamente aceptables y solvatos, que son utiles como inhibidores de la enzima polimerasa del virus de la Hepatitis C (HCV) y tambien son utiles para el tratamiento de infecciones por HCV en mamiferos infectados por HCV. La presente invencion tambien proporciona composiciones farmaceuticas que comprenden compuestos de formula (4), sus sales farmaceuticamente aceptables y solvatos. Ademas, la presente invencion proporciona compuestos intermedios y metodos utiles en la preparacion de compuestos de formula (4).
CR8935A 2004-08-18 2007-02-16 Inhibidores de la arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones CR8935A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60261804P 2004-08-18 2004-08-18

Publications (1)

Publication Number Publication Date
CR8935A true CR8935A (es) 2007-07-24

Family

ID=35429645

Family Applications (2)

Application Number Title Priority Date Filing Date
CR8935A CR8935A (es) 2004-08-18 2007-02-16 Inhibidores de la arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones
CR20110153A CR20110153A (es) 2004-08-18 2011-03-21 Inhibidores de la arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones (divisional solicitud 8935)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20110153A CR20110153A (es) 2004-08-18 2011-03-21 Inhibidores de la arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones (divisional solicitud 8935)

Country Status (42)

Country Link
US (3) US7151105B2 (es)
EP (1) EP1781662B1 (es)
JP (1) JP4372195B2 (es)
KR (1) KR100851178B1 (es)
CN (2) CN101538268B (es)
AP (1) AP2313A (es)
AR (1) AR050699A1 (es)
AT (1) ATE506364T1 (es)
AU (1) AU2005273619B2 (es)
BR (1) BRPI0514425A (es)
CA (1) CA2577525C (es)
CR (2) CR8935A (es)
CY (1) CY1111480T1 (es)
DE (1) DE602005027580D1 (es)
DK (1) DK1781662T3 (es)
EA (1) EA012605B1 (es)
EC (1) ECSP077264A (es)
ES (1) ES2361845T3 (es)
GE (2) GEP20094751B (es)
GT (1) GT200500221A (es)
HN (1) HN2005000449A (es)
HR (1) HRP20110458T1 (es)
IL (2) IL180933A (es)
MA (1) MA28803B1 (es)
MX (1) MX2007001527A (es)
MY (1) MY146123A (es)
NI (1) NI200700043A (es)
NL (1) NL1029755C2 (es)
NO (1) NO20071274L (es)
NZ (1) NZ552874A (es)
PE (1) PE20060677A1 (es)
PL (1) PL1781662T3 (es)
PT (1) PT1781662E (es)
RS (1) RS51794B (es)
SI (1) SI1781662T1 (es)
SV (1) SV2007002202A (es)
TN (1) TNSN07066A1 (es)
TW (1) TWI376379B (es)
UA (1) UA88909C2 (es)
UY (1) UY29068A1 (es)
WO (1) WO2006018725A1 (es)
ZA (1) ZA200700779B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2313A (en) * 2004-08-18 2011-10-31 Pfizer Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same.
EP1928878A1 (en) * 2005-08-24 2008-06-11 Pfizer Inc. Methods for the preparation of hcv polymerase inhibitors
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
EP2008996A1 (en) * 2007-06-27 2008-12-31 Syngeta Participations AG Process for the production of pyrazoles
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びhcv感染の治療におけるその使用
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
KR101616396B1 (ko) 2008-08-11 2016-04-28 글락소스미스클라인 엘엘씨 신규의 아데닌 유도체
EA201100114A1 (ru) 2008-08-11 2011-10-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
PH12012500827A1 (en) 2009-10-30 2013-01-07 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
EP2325173A1 (de) 2009-11-19 2011-05-25 Bayer CropScience AG Verfahren zum Herstellen von 5-Fluor-1-alkyl-3-fluoralkyl-1H-pyrazol-4-carbonsäurechloriden
PH12012501216A1 (en) 2009-12-18 2012-11-05 Boehringer Ingelheim Int Hcv combination therapy
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
EA021048B1 (ru) 2010-02-10 2015-03-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она
KR20170102581A (ko) * 2010-05-20 2017-09-11 바이엘 인텔렉쳐 프로퍼티 게엠베하 1-알킬-3-디플루오르메틸-5-히드록시피라졸의 제조 방법
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
FR2972452B1 (fr) * 2011-03-09 2013-03-15 Rhodia Operations Procede de preparation du difluoroacetonitrile et de ses derives
MX348274B (es) 2012-05-14 2017-06-02 Bayer Cropscience Ag Procedimiento de preparacion de cloruros de 1-alquil-3-fluoroalqui l-1h-pirazol-4-carbonilo.
US9657024B2 (en) 2012-11-21 2017-05-23 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
WO2014111449A1 (en) 2013-01-17 2014-07-24 Bayer Cropscience Ag Process for preparing 5-fluoro-1-methyl-3-difluoromethyl-1h-pyrazole-4-carbaldehyde
KR102191469B1 (ko) 2013-02-06 2020-12-16 바이엘 애니멀 헬스 게엠베하 해충 방제제로서의 할로겐-치환된 피라졸 유도체
EP3089972B1 (de) 2014-01-03 2018-05-16 Bayer Animal Health GmbH Neue pyrazolyl-heteroarylamide als schädlingsbekämpfungsmittel
BR112016016397B1 (pt) 2014-01-24 2021-06-29 Bayer Cropscience Aktiengesellschaft Processo para preparar 1-alquil-3-difluorometil-5- fluoro-1h-pirazol-4-carbaldeídos ou os seus ésteres
JP6452711B2 (ja) 2014-02-20 2019-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited ヒトインターフェロンの誘導物質としてのピロロ[3,2]ピリミジン誘導体
DK3152199T3 (en) 2014-06-03 2018-11-26 Idorsia Pharmaceuticals Ltd PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS
JP2017533925A (ja) 2014-11-13 2017-11-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アレルギー性疾患又は他の炎症状態の治療に有用なアデニン誘導体
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CA3006930A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
PE20181884A1 (es) 2016-04-07 2018-12-07 Glaxosmithkline Ip Dev Ltd Amidas heterociclicas utiles como moduladores de proteinas
ES2781474T3 (es) 2016-04-07 2020-09-02 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
ES2938615T3 (es) 2016-08-15 2023-04-13 Bayer Cropscience Ag Derivados del heterociclo bicíclico condensado como agentes de control de plagas
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3554490B1 (en) 2016-12-16 2022-02-16 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
WO2018141961A1 (en) 2017-02-06 2018-08-09 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
WO2019068572A1 (de) 2017-10-04 2019-04-11 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
CN111417630B (zh) 2017-10-05 2023-06-06 葛兰素史克知识产权开发有限公司 干扰素基因刺激因子(sting)的调节剂
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
WO2019175045A1 (de) 2018-03-12 2019-09-19 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
KR20210005081A (ko) 2018-04-20 2021-01-13 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로시클렌 유도체
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
TWI724753B (zh) 2019-01-25 2021-04-11 大陸商北京賽特明強醫藥科技有限公司 醯胺基橋連雜環類化合物、及其組合物與應用
CN114391015A (zh) 2019-05-16 2022-04-22 斯汀塞拉股份有限公司 苯并[b][1,8]萘啶乙酸衍生物和使用方法
CN114302875A (zh) 2019-05-16 2022-04-08 斯汀塞拉股份有限公司 氧代吖啶基乙酸衍生物及使用方法
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN112194620B (zh) * 2020-12-04 2021-02-26 苏州开元民生科技股份有限公司 一种2-乙基-4-氰基吡啶的制备方法
CN113563167B (zh) * 2021-07-16 2023-09-08 南通华祥医药科技有限公司 一种2-甲基-1-四氢萘酮的制备方法
TW202525795A (zh) 2023-10-31 2025-07-01 日商日本農藥股份有限公司 具有磺醯基之含氮雜環化合物及含有該化合物之農園藝用除草劑、以及其等之使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) * 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
DE2155360C3 (de) * 1971-11-08 1980-04-03 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von Acylbernsteinsäuredialkylestern
CA1144937A (en) * 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
US4326058A (en) * 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) * 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
US5840751A (en) * 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US5504104A (en) * 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
TJ320B (en) * 1993-11-19 2001-10-22 Parke Davis & Co 5,6-Dihydropyrone derivatives as protease inhibitors and antiviral agents
CA2176043A1 (en) 1993-11-19 1995-05-26 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US6005103A (en) * 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US6528510B1 (en) 1998-09-11 2003-03-04 Warner-Lambert Company HIV protease inhibitors
US6512006B1 (en) * 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
AP2313A (en) * 2004-08-18 2011-10-31 Pfizer Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same.

Also Published As

Publication number Publication date
NZ552874A (en) 2010-04-30
EP1781662B1 (en) 2011-04-20
US8268835B2 (en) 2012-09-18
AP2313A (en) 2011-10-31
NL1029755A1 (nl) 2006-02-21
CR20110153A (es) 2011-04-26
ECSP077264A (es) 2007-04-26
PE20060677A1 (es) 2006-08-11
SI1781662T1 (sl) 2011-07-29
BRPI0514425A (pt) 2008-06-10
EA200700338A1 (ru) 2007-08-31
UA88909C2 (ru) 2009-12-10
US20070015764A1 (en) 2007-01-18
HN2005000449A (es) 2009-10-30
TNSN07066A1 (fr) 2008-06-02
AU2005273619B2 (en) 2009-05-28
TWI376379B (en) 2012-11-11
AP2007003918A0 (en) 2007-02-28
TW200612898A (en) 2006-05-01
DE602005027580D1 (de) 2011-06-01
RS51794B (sr) 2011-12-31
AR050699A1 (es) 2006-11-15
ES2361845T3 (es) 2011-06-22
US7622605B2 (en) 2009-11-24
AU2005273619A1 (en) 2006-02-23
ATE506364T1 (de) 2011-05-15
US7151105B2 (en) 2006-12-19
JP2008509984A (ja) 2008-04-03
MA28803B1 (fr) 2007-08-01
CN101538268A (zh) 2009-09-23
CY1111480T1 (el) 2015-08-05
KR20070044057A (ko) 2007-04-26
IL192919A0 (en) 2009-02-11
WO2006018725A1 (en) 2006-02-23
IL180933A0 (en) 2007-07-04
GEP20115305B (en) 2011-10-10
DK1781662T3 (da) 2011-06-27
GT200500221A (es) 2006-06-21
EA012605B1 (ru) 2009-10-30
UY29068A1 (es) 2006-03-31
HRP20110458T1 (hr) 2011-07-31
SV2007002202A (es) 2007-03-20
MX2007001527A (es) 2007-03-27
HK1109617A1 (en) 2008-06-13
CN101538268B (zh) 2011-07-27
EP1781662A1 (en) 2007-05-09
PT1781662E (pt) 2011-07-01
KR100851178B1 (ko) 2008-08-08
NI200700043A (es) 2008-01-02
GEP20094751B (en) 2009-08-10
CA2577525C (en) 2010-03-30
PL1781662T3 (pl) 2011-08-31
CN101006092B (zh) 2013-04-17
US20060122399A1 (en) 2006-06-08
CN101006092A (zh) 2007-07-25
IL180933A (en) 2011-08-31
NO20071274L (no) 2007-05-14
JP4372195B2 (ja) 2009-11-25
MY146123A (en) 2012-06-29
ZA200700779B (en) 2008-11-26
US20090281122A1 (en) 2009-11-12
CA2577525A1 (en) 2006-02-23
NL1029755C2 (nl) 2006-10-18

Similar Documents

Publication Publication Date Title
CR8935A (es) Inhibidores de la arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones
PA8596001A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan
MX2007004783A (es) Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
NO20060979L (no) Nye tricykliske nukleosider eller nukleotider som terapeutiske midler
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
CU23787B7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
CL2011000136A1 (es) Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c.
BRPI0508217A (pt) cetamidas com p4's cìclico como inibidores de ns3 serina protease de vìrus de hepatite c
EA200901241A1 (ru) Соединения для лечения гепатита с
CO6382185A2 (es) Compuestos nucleosidos antivirales
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
ECSP12012147A (es) Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales
NI201300107A (es) Derivados de nucleósidos 2' - sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales.
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
BRPI0815920A2 (pt) Composto, composição farmacêutica, e, uso do composto.
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
UY31685A (es) Compuestos antivirales, composiciones y metodos para usarlos
CY1118729T1 (el) Παραγωγα 9-μεθυλ υποκατεστημενου εξαδεκαϋδροκυκλοπροπα(ε)πυρρολο(1,2-α)(1,4)διαζακυκλοπενταδεκινυλ καρβαμικου ως μη δομικοι 3 (ns3) αναστολεις πρωτεασης για την αγωγη λοιμωξεων απο ιο ηπατιτιδας c
GT200600262A (es) Uso de la sangliferina en el hcv (virus de la hepatitis "c")
DOP2005000165A (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan